Intensive Glycemic Control and Skeletal Health Study (ACCORD-BONE)
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the ACCORD-BONE Study is to investigate the effects of intensive glycemic control for type 2 diabetes (in ACCORD participants) on factors related to bone health, including, fractures, falls, and bone mineral density.
| Condition | Intervention | Phase |
|---|---|---|
|
Atherosclerosis Cardiovascular Diseases Hypercholesterolemia Hypertension Diabetes Mellitus Coronary Disease |
Drug: hypoglycemic agents, hydroxymethylglutaryl-CoA Reductase inhibitors, hypertensive agents |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Factorial Assignment Masking: Single Blind (Investigator) Primary Purpose: Prevention |
| Official Title: | Intensive Glycemic Control and Skeletal Health Study - Ancillary Study to the Action to Control Cardiovascular Risk in Diabetes Trial (ACCORD-BONE) |
- Number of Participants With at Least One Non-vertebral Fracture [ Time Frame: Average follow-up of 3.8 years ] [ Designated as safety issue: No ]The BONE ancillary study was initiated during recruitment for the main ACCORD trial. Beginning in January 2006, at the next annual visit participants were asked about the occurrence of any non-spine fractures since randomization. After the annual visit in 2006, participants were asked if they had suffered a fracture since their last annual visit. Reported fracture events were centrally adjudicated, based on radiology records, at the University of California, San Francisco (UCSF) with the adjudicators blinded to treatment assignment.
- Number of Participants With at Least One Fall [ Time Frame: Average follow-up of 2.0 years ] [ Designated as safety issue: No ]At each annual visit starting in January 2006, participants were also asked about falling: "In the last 12 months have you fallen and landed on the floor or ground, OR fallen and hit an object like a table or stair?" Those who answered "yes" were also asked how many times they had fallen in the previous 12 months.
- Number of Participants With > 2 cm of Height Loss [ Time Frame: 5 years ] [ Designated as safety issue: No ]Standing height was measured according to a standard protocol at baseline and annual visits on all ACCORD participants. Height loss was compared by treatment assignment using linear mixed models with random intercepts and slopes. Treatment effects were captured by the interaction between treatment assignment and time. The proportions losing >2 cm of height during follow-up were compared using logistic models. This degree of height loss is associated with incident vertebral fracture with 94% specificity but only 28% sensitivity
| Enrollment: | 7287 |
| Study Start Date: | October 2003 |
| Study Completion Date: | June 2009 |
| Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1
intensive glycemic control (therapeutic strategy that targets a glycosylated hemoglobin (HbA1c) level below 6.0%)
|
Drug: hypoglycemic agents, hydroxymethylglutaryl-CoA Reductase inhibitors, hypertensive agents
type 2 diabetes treatments, per standard of care
|
|
Active Comparator: 2
standard glycemic control (therapeutic strategy that targets a glycosylated hemoglobin (HbA1c) level of 7 to 7.9%)
|
Drug: hypoglycemic agents, hydroxymethylglutaryl-CoA Reductase inhibitors, hypertensive agents
type 2 diabetes treatments, per standard of care
|
Detailed Description:
Recent studies have established that type 2 diabetes is a risk factor for fractures, particularly of the hip, shoulder and foot. Additionally, type 2 diabetes is associated with a 50-60% increase in the risk of falling. The higher risk of fracture associated with type 2 diabetes is an important health burden for these patients. More frequent falls and perhaps reduced bone strength in those with diabetes are thought to be key contributing factors. The best approach to preventing fractures in type 2 diabetes is not yet understood. There is observational evidence to support our hypothesis that better glycemic control will preserve bone and reduce falls and fractures. The ACCORD-BONE study provides a unique opportunity to determine whether intensive glycemic control will prevent fractures, falls, and bone loss in older diabetic adults, which may lead to improved treatment and prevention in the future.
Eligibility| Ages Eligible for Study: | 40 Years to 79 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion criteria:
- Fulfills criteria for inclusion in the ACCORD main trial
- Must have been randomized into the ACCORD study and be a participant from the five CCNs in the ACCORD-BONE ancillary study.
Exclusion criteria:
- Fulfills criteria for exclusion in the ACCORD main trial
Contacts and Locations| United States, Minnesota | |
| Berman Center for Outcomes & Clinical Research | |
| Minneapolis, Minnesota, United States, 55404 | |
| United States, North Carolina | |
| Wake Forest University | |
| Winston-Salem, North Carolina, United States, 27106 | |
| United States, Ohio | |
| Case Western Reserve University | |
| Cleveland, Ohio, United States, 44106 | |
| United States, Tennessee | |
| Veterans Affairs | |
| Memphis, Tennessee, United States, 38104 | |
| Canada, Ontario | |
| Population Health Research Institute | |
| Hamilton, Ontario, Canada | |
| Principal Investigator: | Ann V. Schwartz, PhD | University of California, San Francisco |
More Information
Additional Information:
No publications provided by University of California, San Francisco
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | University of California, San Francisco |
| ClinicalTrials.gov Identifier: | NCT00324350 History of Changes |
| Other Study ID Numbers: | R01-DK069514 |
| Study First Received: | May 10, 2006 |
| Results First Received: | March 15, 2012 |
| Last Updated: | September 5, 2012 |
| Health Authority: | United States: Federal Government |
Keywords provided by University of California, San Francisco:
|
Diabetes Mellitus Fracture Falls Height Loss |
Additional relevant MeSH terms:
|
Atherosclerosis Cardiovascular Diseases Coronary Disease Coronary Artery Disease Diabetes Mellitus Hypercholesterolemia Hypertension Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Myocardial Ischemia Heart Diseases Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
Hyperlipidemias Dyslipidemias Lipid Metabolism Disorders Hypoglycemic Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Physiological Effects of Drugs Pharmacologic Actions Anticholesteremic Agents Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Enzyme Inhibitors Lipid Regulating Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 21, 2013